ArticleBMC infectious diseases2025
Relation between serum magnesium and outcome in patients with Escherichia coli sepsis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveEscherichia coli (E.coli) is the leading pathogen for deaths associated with antimicrobial resistance, making it the most problematic bacteria for human infections. This study aimed to investigate the association between serum magnesium levels and clinical outcomes in patients with E.coli sepsis.
methodData of E.coli septic patients were collected from the MIMIC-IV database. Patients were divided into three groups based on tertiles of serum magnesium levels. Three models were utilized, including the raw model (unadjusted), Model I (adjusted for age and gender), and Model II (adjusted for all potential confounding factors). Linear model and two-segment nonlinear model were established to examine the relationship between serum magnesium and 30-day, 60-day, and 90-day mortality rates. Kaplan-Meier survival curve analysis was performed to assess cumulative hazard of mortalities at 30-day, 60-day, 90-day based on tertiles of serum magnesium levels.
resultsA total of 421 E.coli septic patients were included and classified into tertiles: Q1(< 1.6 mg/dL), Q2 (1.6-1.9 mg/dL), Q3(> 1.9 mg/dL). In the Model adjusting for all potential confounders, for every 1 mg/dL increase in serum magnesium, there was a significant increase in 30-day, 60-day, and 90-day mortality rates, with odds ratios of 4.01 (95% CI 1.22-13.19, P = 0.022), 4.81 (95% CI 1.59-14.53, P = 0.005), and 4.45 (95% CI 1.52-12.96, P = 0.006) respectively. And linear model is more suitable for describing the relationship between serum magnesium levels and clinical outcomes. Kaplan-Meier analysis revealed that the cumulative hazard of mortalities at 30-day, 60-day, 90-day increased with the prolongation of hospital stay, particularly in the group with the highest serum magnesium level.
conclusionIncreased level of serum magnesium is significantly associated with increased risk of 30-day, 60-day and 90-day mortality in a population of septic patients with E.coli infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.